napabucasin + bortezomib

A combination investigational regimen comprising **napabucasin** and **bortezomib**, each with distinct anticancer mechanisms. Napabucasin is a small molecule cancer stemness inhibitor, functioning primarily as a STAT3 inhibitor and interfering with cancer cell self-renewal and survival. Bortezomib is a small molecule proteasome inhibitor, disrupting protein degradation in malignant cells, leading to apoptosis. The combination is under early investigation as a potential synergistic therapy in certain cancers (notably multiple myeloma or solid tumors), but is not an established or approved combination regimen as of the current date.